This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
by Zacks Equity Research
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.
AZNPositive Net Change NVOPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Bet on 5 High ROE Stocks as Markets Shrug Off Oil Output Cut
by Supriyo Bose
AutoNation (AN), Suzano (SUZ), Valero Energy (VLO), Hologic (HOLX) and Ryder (R) are some of the stocks with high ROE to profit from as markets rise despite lower oil production.
RNegative Net Change VLONegative Net Change ANNegative Net Change HOLXPositive Net Change SUZNegative Net Change
auto-tires-trucks biofuels biotechnology industrial-products transportation
Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.
NVSPositive Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs pharmaceuticals
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
by Zacks Equity Research
Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.
NVSPositive Net Change JNJPositive Net Change NVOPositive Net Change INVANegative Net Change
biotechnology medical
5 Stocks With Recent Price Strength Amid March Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.
CRD.BPositive Net Change BLPHPositive Net Change LNTHNegative Net Change HROWNegative Net Change REPXNegative Net Change
biotechnology business-services energy medical
bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4
by Zacks Equity Research
bluebird (BLUE) provides updates on its BLA submission for its experimental gene therapy lovo-cel and reports Q4 results. Shares are down on the same.
NVOPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSKPositive Net Change NVOPositive Net Change SCYXNegative Net Change JSPRNegative Net Change
biotechnology medical vaccines
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
by Zacks Equity Research
Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
EBSNegative Net Change CRSPNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology medical vaccines
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
REGNNegative Net Change INCYPositive Net Change VKTXNegative Net Change BMEANegative Net Change
biotechnology biotechs
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
by Zacks Equity Research
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
NVOPositive Net Change VKTXNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology medical
4 Best Breakout Stocks to Buy Now for Superlative Returns
by Tirthankar Chakraborty
CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.
CBAYPositive Net Change RELYNegative Net Change UWMCPositive Net Change RXSTPositive Net Change
biotechnology tech-stocks
DOW Launches Six Sustainable Products at in-cosmetics Global
by Zacks Equity Research
DOW personal care unveils six new products at in-cosmetics global 2023 to further speed up its ongoing transformation toward a sustainable portfolio.
STLDPositive Net Change DOWNo Net Change ZEUSPositive Net Change LINNegative Net Change
basic-materials biotechnology
Unity (UNX) Down on Disappointing Results From Wet AMD Study
by Zacks Equity Research
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
REGNNegative Net Change BAYRYPositive Net Change
biotechnology pharmaceuticals
Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU
by Zacks Equity Research
Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
BMYPositive Net Change NVOPositive Net Change AMGNPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
by Zacks Equity Research
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
FOLDPositive Net Change CRSPNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology medical
Bear of the Day: BioNTech (BNTX)
by Andrew Rocco
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.
PFEPositive Net Change BNTXNegative Net Change
biotechnology biotechs coronavirus
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
INCYPositive Net Change CRSPNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology medical
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
MRNANegative Net Change CRSPNegative Net Change GBIONegative Net Change JSPRNegative Net Change
biotechnology gene-therapy medical
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
BIIBPositive Net Change GILDNegative Net Change INCYPositive Net Change ALTPositive Net Change
biotechnology biotechs pharmaceuticals
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
by Zacks Equity Research
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
NVSPositive Net Change NVOPositive Net Change INCYPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
by Zacks Equity Research
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
CRSPNegative Net Change BHVNNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology medical
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
by Zacks Equity Research
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
NVOPositive Net Change GILDNegative Net Change LGNDPositive Net Change NRIXPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
by Zacks Equity Research
Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
REGNNegative Net Change SNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
UiPath (PATH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PATHNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
by Zacks Equity Research
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
NTLANegative Net Change CRSPNegative Net Change KALAPositive Net Change JSPRNegative Net Change
biotechnology crispr gene-therapy medical